866-997-4948(US-Canada Toll Free)

EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024

Published By :

GlobalData

Published Date : Dec 2015

Category :

Pharmaceutical

No. of Pages : 55 Pages

EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024

Summary

The Hepatitis B Virus (HBV) can cause both acute and chronic liver disease. HBV is typically transmitted through contact with infectious blood or bodily fluid, including vertical transmission from mother to child at birth and transmission via sexual intercourse. Risk factors of chronic hepatitis B (CHB) include unprotected sex with an infected partner, men who have sex with men (MSM), intravenous drug injection (IDU), and a previous history of a sexually transmitted disease (STD). CHB has a well-established comorbidity association with hepatitis C virus (HCV) infection, hepatitis D virus (HDV) infection, human immunodeficiency virus (HIV) infection, and alcohol abuse. The disease often starts as asymptomatic in the acute infection phase, with symptoms beginning to present 30 to 180 days from infection. When symptoms develop, they present as nausea, vomiting, loss of appetite, flu-like symptoms, and jaundice. Severe cases of HBV infection increase the risk of developing liver cancer and cirrhosis.

GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of chronic hepatitis B (CHB) in the 8MM, from 10,557,407 cases in 2014 to 10,861,653 cases in 2024, at an Annual Growth Rate (AGR) of 0.29% in the forecast period. The distribution of diagnosed prevalent chronic hepatitis B cases in the 8MM was greater in men (7,379,948 cases, 69.90% in 2014) than in women (3,177,459 cases, 30.10% in 2014). This skew towards men was found to be consistent across all markets.

GlobalDatas epidemiological forecast for the diagnosed prevalent cases of CHB are supported by age- and sex-specific data obtained from country-specific studies published in peer-reviewed journals, in which the study populations are representative of the general population in the respective markets. The diagnosed prevalent cases are further segmented into ALT level, HBV DNA level, HBeAg status, cirrhosis status, and co-infection with hepatitis C and HIV, thus providing a comprehensive view of the characteristics of CHB patients in the 8MM. Additionally, GlobalData epidemiologists used the same methodology across the 8MM, which allows for a meaningful comparison of the forecast diagnosed incident cases and diagnosed prevalent cases of CHB in these markets.

Scope

- The Chronic Hepatitis B (CHB) EpiCast Report provides an overview of the risk factors and global trends of CHB in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China). It includes a 10-year epidemiological forecast for total and diagnosed prevalent cases of CHB segmented by sex and in these markets. The diagnosed prevalent cases of CHB are further segmented by hepatitis B virus (HBV) DNA level (<2000IU/mL, 2,000-20,000IU/mL, and >20,000IU/mL in the US and the 5EU, and <1000IU/mL, 1,000-10,000IU/mL, and >10,000IU/mL in Japan and China), alanine aminotransferase (ALT) level (=2 upper limit of normal [ULN] 2-5ULN and >5ULN), hepatitis e surface antigen (HBeAg) status, and the liver cirrhosis status.
- The CHB epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The CHB EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global CHB market.
- Quantify patient populations in the global CHB market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CHB therapeutics in each of the markets covered.
- Identify the percentage of CHB diagnosed prevalent cases by various clinical segmentations.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 9
3 Epidemiology 10
3.1 Disease Background 10
3.2 Risk Factors and Comorbidities 11
3.3 Global Trends 12
3.4 Forecast Methodology 14
3.4.1 Sources Used 15
3.4.2 Sources Not Used 24
3.4.3 Forecast Assumptions and Methods 25
3.5 Epidemiological Forecast of Chronic Hepatitis B (2014-2024) 31
3.5.1 Diagnosed Prevalent Cases of Chronic Hepatitis B 31
3.5.2 Age-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B 33
3.5.3 Sex-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B 36
3.5.4 Age-Standardized Diagnosed Prevalence of Chronic Hepatitis B 38
3.5.5 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBV DNA Level 39
3.5.6 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by ALT Level 41
3.5.7 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBeAg Status 42
3.5.8 Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by Cirrhosis Status 43
3.5.9 Diagnosed Prevalent Cases of Chronic Hepatitis B with Co-infection of HIV and Hepatitis C 45
3.6 Discussion 46
3.6.1 Epidemiological Forecast Insight 46
3.6.2 Limitations of the Analysis 46
3.6.3 Strengths of the Analysis 47
4 Appendix 48
4.1 Bibliography 48
4.2 About the Authors 51
4.2.1 Epidemiologists 51
4.2.2 Reviewers 51
4.2.3 Global Director of Therapy Analysis and Epidemiology 52
4.2.4 Global Head of Healthcare 52
4.3 About GlobalData 53
4.4 About EpiCast 53
4.5 Disclaimer 54

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Chronic Hepatitis B 12
Table 2: 8MM, Sources Used for the Diagnosed Prevalent Cases Forecast of Chronic Hepatitis B in the 8MM 15
Table 3: 8MM, Sources Used for HBV DNA Level 16
Table 4: 8MM, Sources Used for Chronic Hepatitis B by ALT Level 16
Table 5: 8MM, Sources Used for Chronic Hepatitis B HBeAg Status 17
Table 6: 8MM, Sources Used for Cirrhosis Status 18
Table 7: 8MM, Sources Used for HIV Co-infection 19
Table 8: 8MM, Sources Used for Hepatitis C Co-infection 20
Table 9: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B, Both Sexes, All Ages, Select Years, 2014-2024 32
Table 10: 8MM, Age-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages 18 Years, N (Row %), 2014 34
Table 11: 8MM, Sex-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages 18 Years, N, 2014 37
Table 12: US and 5EU, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBV DNA, Ages 18 Years, N, Both Sexes, 2014 40
Table 13: Japan and China, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBV DNA, Ages 18 Years, N, Both Sexes, 2014 40
Table 14: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by ALT Level, Ages 18 Years, N, Both Sexes, 2014 42
Table 15: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented by HBeAg Status, Ages 18 Years, N, Both Sexes, 2014 43
Table 16: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B Segmented Cirrhosis Status, Ages 18 Years, N, Both Sexes, 2014 44
Table 17: 8MM, Diagnosed Prevalent Chronic Hepatitis B Cases Segmented by Co-infection with HIV and Hepatitis C, Both Sexes, Ages 18 Years, N (% of Diagnosed Chronic Hepatitis B Cases), 2014 45

1.2 List of Figures
Figure 1: 8MM, Diagnosed Prevalent Cases of Chronic Hepatitis B, Both Sexes, Ages 18 Years, Select Years, 2014-2024 33
Figure 2: 8MM, Age-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages 18 Years, Both Sexes, N, 2014 35
Figure 3: 8MM, Sex-Specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Ages 18 Years, N, 2014 38
Figure 4: 8MM, Age-Standardised Diagnosed Prevalence of Chronic Hepatitis B, Ages 18 Years, 2014 39

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Oral Proteins And Peptides Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

    Pharmaceutical formulations containing proteins and peptides are usually administered via intravenous or subcutaneous route of administration, because instability and sensitivity towards body fluids. However, owing to rising R&D activities and technological advancements, the researchers have successfully developed protein formulations that are orally administered with no change in therapeutic activity and pharmacokinetic aspects.The market ...

  • AFP Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019

    Alpha-fetoprotein (AFP) is the most widely found plasma protein in human fetus.  The AFP protein found in humans is encoded by the AFP gene that is located on chromosome 4.  It is a major plasma protein which is produced during fetal development in yolk sac and the liver.  AFP is a glycoprotein which is found in monomeric, dimeric and trimeric forms. The protein is normally made by immature liver cells in the fetus therefore; inf...

  • Delirium Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019

    Delirium is a serious mental disorder, which can cause two most common type of behaviors, namely, hyperactive behavior, which is characterized by severe confusion, disorientation and disturbance in consciousness that fluctuates and hypoactive behavior, which is characterized by the sudden onset of withdrawal from interaction with the outside world. This serious mental disorder is mainly caused due to physical or mental illnesses, which is tempora...